PLAC™ test for identification of individuals at increased risk for coronary heart disease

Expert Review of Molecular Diagnostics

Volumn 5, Issue 1, 2005, Pages 9-14

  Hoogeveen, Ron C ^a   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Inflammatory markers; Lipoprotein associated phospholipase A2; PLAC test; Suboxidative stress

Indexed keywords

BIOLOGICAL MARKER; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A(2); LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2); PHOSPHOLIPASE A;

BLOOD CHEMISTRY; CLINICAL TRIAL; CORONARY RISK; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PERFORMANCE; PLAC TEST; POPULATION RESEARCH; REVIEW; SCREENING TEST; ARTICLE; BLOOD; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; METABOLISM; PROGNOSIS; RISK FACTOR;

BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; HUMANS; PHOSPHOLIPASES A; PROGNOSIS; RISK FACTORS;

EID: 12344308132     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.5.1.9     Document Type: Review

References (52)

1. American Heart Association. Heart and Stroke Statistics - 2004 Update. American Heart Association, TX, USA, 5-6 (2003).
2. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792 (1991).
4. Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21, 844-848 (2001).
5. Sanchez-Quesada JL, Camacho M, Anton R et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166, 261-270 (2003).
6. Hodis HN, Kramsch DM, Avogaro P et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J. Lipid Res. 35, 669-677 (1994).
7. De Castellarnau C, Sanchez-Quesada JL, Benitez S et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 2281-2287 (2000).
8. Demuth K, Myara I, Chappey B et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vasc. Biol. 16, 773-783 (1996).
9. Palmantier R, Dulioust A, Maiza H, Benveniste J, Ninio E. Biosynthesis of paf-acether. XIV. Paf-acether output in murine peritoneal macrophages is regulated by the level of acetylhydrolase. Biochem. Biophys. Res. Commun. 162, 475-482 (1989).
10. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor acetylhydrolase increases during macrophage differentiation: a novel mechanism that regulates accumulation of platelet-activating factor. J. Biol. Chem. 264, 8467-8470 (1989).
11. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J. Biol. Chem. 262, 4223-4230 (1987).
12. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262, 4215-4222 (1987).
13. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15, 1764-1773 (1995).
14. Benitez S, Sanchez-Quesada JL, Ribas V et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108, 92-96 (2003).
15. Tsimihodimos V, Karabina SA, Tambaki AP et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 43, 256-263 (2002).
16. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J. Biol. Chem. 272, 17895-17898 (1997).
17. Stafforini DM, Satoh K, Atkinson DL et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J. Clin. Invest. 97, 2784-2791 (1996).
18. 2 with a catalytic triad. J. Biol. Chem. 270, 25481-25487 (1995).
19. Tew DG, Southan C, Rice SQ et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16, 591-599 (1996).
20. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266, 11095-11103 (1991).
21. 2 reduces LDL degradation and foam cell formation in vitro. J. Lipid Res. 45, 1633-1639 (2004).
22. Hase M, Tanaka M, Yokota M, Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat. 70, 107-118 (2002).
23. -/. mice. FASEB J. 14, 2032-2039 (2000).
24. Quarck R, De Geest B, Stengel D et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103, 2495-2500 (2001).
25. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerosis lesions. Arterioscler. Thromb. Vasc. Biol. 19, 2909-2917 (1999).
26. Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin. Sci. (Lond.) 106, 421-432 (2004).
27. Opal S, Laterre PF, Abraham E et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32, 332-341 (2004).
28. Miwa M, Miyake T, Yamanaka T et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 82, 1983-1991 (1988).
29. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb. Res. 101, 231-234 (2001).
30. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke 28, 2417-2420 (1997).
31. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150, 209-216 (2000).
32. Shimokata K, Yamada Y, Kondo T et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 172, 167-173 (2004).
33. Unno N, Nakamura T, Kaneko H et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J. Vasc. Surg. 32, 263-267 (2000).
34. Unno N, Nakamura T, Mitsuoka H et al. Association of a G994→T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann. Surg. 235, 297-302 (2002).
35. Ishihara M, Iwasaki T, Nagano M et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J. Hum. Genet. 49, 302-307 (2004).
36. Bell R, Collier DA, Rice SQ et al. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem. Biophys. Res. Commun. 241, 630-635 (1997).
37. Kruse S, Mao XQ, Heinzmann A et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet. 66, 1522-1530 (2000).
38. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168, 283-238 (2003).
39. Ninio E, Tregouet D, Carrier J-L et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mol. Genet. 13, 1341-1351 (2004).
40. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150, 413-419 (2000).
41. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343, 1148-1155 (2000).
42. 2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38, 1302-1306 (2001).
43. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109, 837-842 (2004).
44. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110, 1903-1908 (2004).
45. Hofman A. Lipoprotein-associated phospholipase A2 is associated with risk of coronary heart disease and stroke. The Rotterdam study. Presented at European Society of Cardiology Congress 2004, Munich, Germany August 31, 2004.
46. Shahar E, Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34, 623-631 (2003).
47. 2, high-sensitivity C-reactive protein, and risk for incident stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Presented at 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, San Francisco, CA, May 8 (2004).
48. New test predicts heart risk. FDA Consum. 37, 6 (2003).
49. 2: an emerging biomarker of coronary heart disease. Expert Rev. Mol. Diagn. 2, 17-22 (2002).
50. Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J. Lipid Res. 42, 1645-1654 (2001).
51. 2.
52. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278, 3937-3947 (2003).